Research
Research areas are derived from OpenAlex topics of their publications.
From the 150 most recent of 154 publications.
Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary disease
Kaczmarek S, Jo D, Ghaziasgar S, Marr B, Berton S, Wang L, Arbabi Ghahroudi M, Jang M, Visram A, McComb S
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O
Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma
Mian H, Arribas M, Fonseca R, Mutterback E, Shahid O, Gouda R, Pond GR, Visram A
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
Haider I, Leong DP, Shahid O, Louzada M, McCurdy A, Pond GR, Cameron R, Balitsky AK, Britto J, Aljama M
Second primary malignancy in multiple myeloma: does a prior malignancy matter?
Visram A, Seow H, Chakraborty R, Pond G, Gayowsky A, Mohyuddin GR, Al Hadidi S, Hansen DK, Sidana S, Gouda R
High prevalence of iron deficiency among daratumumab‐treated newly diagnosed multiple myeloma patients
Hwa YL, Jevremovic D, Pak K, Kapoor P, Visram A, Gertz MA, Dingli DD, Buadi FK, Go RS, Warsame R
Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders
Koo E, Albert S, Patrick B, Henia M, Rhiwi Y, McCudden C, Jimenez Zepeda V, Sandhu I, Chu M, Mian H
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
Mainou M, Alsadhan M, Tsapa K, Visram A, Mian H, Popat R, K E, Chakraborty R, Al Hadidi S, Mohan M
BCMA-CAR Natural Killer Cells Suppress Myeloma in Bone Marrow but Allow Emergence of Extramedullary Disease 2266680
Lee S-H, Kaczmarek S, Ghaziasgar S, Berton S, Ghahroudi MA, Jang M, McComb S, Visram A
Relapsing, steroid-refractory ICANS after CAR T-cell therapy: diagnostic work-up and response to delayed repeated intrathecal chemotherapy
van Nijendaal RM, Vermaat JSP, Geraedts VJ, Dekker TJA, van der Meulen M
Research institutes and memberships
- Escarpment Cancer Research Institute (ECRI) (Joint Institute)
Frequent collaborators
13Researchers with similar interests
Hira Mian
Oncology
Multiple Myeloma Research and Treatments, Cancer Treatment and Pharmacology
Mohammed Aljama
Oncology
Multiple Myeloma Research and Treatments, Cancer Treatment and Pharmacology
Amaris Karin Balitsky
Oncology
Multiple Myeloma Research and Treatments
Tom Kouroukis
Oncology
Multiple Myeloma Research and Treatments
Gregory Pond
Oncology
Cancer Treatment and Pharmacology
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.